CEO Executive AssistantRare disease patient journey leadership is among the most distinctive aspects of running a specialty rare disease company. In contrast to large-cap pharma, where patient experience is mediated through layers of medical affairs, advocacy relations, and commercial infrastructure, rare disease CEOs frequently find themselves directly engaged with patient families, disease community leaders, and patient registries in ways that have no counterpart in other therapeutic areas.
This proximity to the patient community is a strategic asset, not just an ethical commitment. Rare disease companies that have deep, direct knowledge of the patient journey consistently produce better trial designs, achieve faster enrollment, build stronger regulatory submissions, and create more compelling commercial launches. The CEO’s time investment in understanding and advocating for patient journeys is not goodwill spending. It is competitive advantage.
Understanding the Rare Disease Patient Journey
The patient journey in a rare disease is typically arduous in ways that are not well-understood from a drug development perspective. Patients – often children – experience years of diagnostic odyssey before a definitive diagnosis. They and their families navigate fragmented specialist care, incomplete natural history data, and limited or nonexistent treatment options. When a clinical trial opens, it is often the first treatment option families have encountered.
CEOs who understand this journey – not abstractly but through direct engagement with patients and families – bring a different lens to the development decisions that matter: inclusion/exclusion criteria that may unnecessarily exclude patients, endpoint definitions that may not capture what matters most to families, and patient burden considerations that affect trial retention and data quality.
This understanding cannot be fully delegated to a patient affairs team. The CEO who has spent time with patient families at a disease foundation conference carries that knowledge into scientific advisory board discussions, protocol reviews, and investor conversations in ways that transform the quality of decision-making.
Building Patient Journey Knowledge Into Your Calendar
Attend at Least One Patient Community Event Per Year
For most rare disease companies, there is a flagship annual meeting or patient family conference organized by the primary disease foundation. This event – often attended by hundreds of patient families, scientific advisors, and clinicians – is the most efficient single opportunity to develop direct patient journey knowledge.
CEO attendance at this event signals to the patient community that your company’s leadership is engaged at the most human level. But the value for the CEO is not symbolic. In a single day, you can have ten to fifteen conversations with patients and families that give you ground-level understanding of what the disease means in daily life, what patients fear most about the treatment options available, and what a successful outcome actually looks like from their perspective.
Budget two days for this event per year per lead therapeutic area: one day for the conference and family meetings, one day for related scientific or advisory meetings that often cluster around the same time.
Patient Advisory Councils
Many rare disease companies have established patient advisory councils: small groups of patients and caregivers who advise on trial design, patient burden, and access programs. CEOs who participate directly in these meetings – even quarterly, even for 30 to 45 minutes – extract insights that change how programs are designed.
The specific value is in hearing unfiltered perspectives on the questions you are actually asking: What is the most burdensome aspect of trial participation? What outcome would be most meaningful to you and your family? What concerns do you have about this approach to treatment? These are not questions your market research team can answer on your behalf.
One-on-One Patient Family Conversations
There is no substitute for direct, unstructured conversation with a patient family. For rare disease CEOs, one to two such conversations per quarter – arranged through your patient affairs team, through disease foundations, or through patient registries – provide qualitative depth that aggregate data and advisory meetings cannot.
These conversations take 45 to 60 minutes. They are not focus groups or advisory meetings with formal agendas. They are honest exchanges between a CEO who wants to understand and a family who wants to be understood. Many rare disease CEOs report that these conversations are among the most consequential uses of their time – not because they produce immediate decisions, but because they fundamentally shape how the CEO thinks about the company’s mission and the decisions that affect patients.
Translating Patient Journey Knowledge Into Development Decisions
The CEO’s patient journey knowledge is most valuable when it enters development decisions at the right moments.
Protocol Design
When your clinical team presents a Phase III protocol, your patient journey knowledge should generate specific questions: Does the visit schedule impose an unreasonable burden on families who must travel? Are the outcome measures capturing what matters to patients, or just what is measurable? Will the inclusion criteria exclude patients who most need this treatment?
Your clinical operations and medical team should be expected to account for patient burden in protocol design. The CEO’s role is to hold them accountable for this, not to redesign the protocol personally.
Regulatory Submissions
FDA’s Patient-Focused Drug Development initiative and the resulting guidance documents create pathways for incorporating patient experience data into regulatory submissions. Rare disease companies have a natural advantage here: they often have direct, longitudinal relationships with patient communities that can generate structured patient experience data.
Your regulatory strategy should explicitly include a patient experience data component. This is not supplementary – it is core to the type of submission that reflects your company’s genuine engagement with patient communities and that resonates with FDA reviewers who have seen thousands of clinical data packages but fewer that authentically reflect patient priorities.
Natural History Studies and Patient Registries
CEOs of rare disease companies should understand the natural history of their target disease in clinical and human terms. Natural history studies and patient registries are the tools your scientific team uses to characterize disease progression. But the CEO’s engagement with patient registries – understanding what data is collected, what families have agreed to contribute, and what the registry organization means to the community – creates a relationship with the registry leadership that is strategically valuable.
Registry organizations often sit at the center of the patient community network. Their leaders know every major investigator, every family conference organizer, and every advocacy organization in the space. A CEO who has taken the time to understand the registry’s mission and has built a genuine relationship with its leadership has a network multiplier that few commercial activities can match.
Advocacy in the Rare Disease Context
Rare disease CEOs often find themselves advocating in contexts that general pharma CEOs do not face: testifying before FDA patient advisory committees, speaking with congressional staff about rare disease drug approval policy, or engaging with international patient organizations on access.
This advocacy is part of the CEO’s role and requires preparation and time investment. Congressional and regulatory engagement on rare disease policy issues – Accelerating Kids’ Access to Care, Rare Pediatric Disease Priority Review Vouchers, pediatric rare disease clinical trial design guidance – matters to your regulatory strategy and to your patients.
Your government affairs team supports this advocacy, but the CEO’s personal voice on rare disease issues carries weight that a trade association or lobbyist cannot replicate. Budget time specifically for one to two regulatory or policy engagement activities per year where your personal participation matters.
Connecting this advocacy to board reporting pharma ensures your board understands the policy environment affecting your programs and can support resource decisions for advocacy and access initiatives.
The Ethical Dimension of Rare Disease Patient Journey Leadership
Rare disease CEOs operate under a specific ethical tension: you are developing therapies for patients who have no alternatives, which creates enormous goodwill and also enormous responsibility. When trials fail, when approvals are delayed, or when pricing prevents access, the human cost is visible in ways that therapeutic area CEOs in larger markets rarely face so directly.
Leading with genuine commitment to the patient journey means being honest with patient communities when things go wrong: when trial results are disappointing, when a regulatory decision is unfavorable, or when access challenges will limit who can benefit from your therapy. Patient communities in rare disease are sophisticated. They prefer honesty to communications management.
CEOs who have built genuine relationships with these communities have the credibility to deliver difficult news in ways that maintain trust. Those who have only been present during good news discover that patient advocacy organizations are a different kind of stakeholder in a crisis.
Conclusion
Rare disease patient journey leadership is not a compliance activity or a reputational investment. It is a core strategic capability that improves clinical program design, regulatory submissions, and commercial launches, while creating organizational conviction about the work’s importance. The time investment – two to four days per year at patient community events, quarterly patient advisory council participation, and a handful of direct patient family conversations – is modest relative to the compounding return it generates across every aspect of how your company develops and delivers therapies.
Related Reading
For further context, explore Pharma CEO Time Management for Autoimmune Disease Strategy and Biomarker-Driven Trial Management: What Pharma CEOs Must Decide and When.